Literature DB >> 21394813

Getting to grips with the new European Union pharmacovigilance legislation.

Patrick Waller1.   

Abstract

Mesh:

Year:  2011        PMID: 21394813     DOI: 10.1002/pds.2119

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


× No keyword cloud information.
  4 in total

Review 1.  Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.

Authors:  Anjan Kumar Banerjee; Inge M Zomerdijk; Stella Wooder; Simon Ingate; Stephen J Mayall
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

2.  Risk minimization activities of centrally authorized products in the EU: a descriptive study.

Authors:  Inge M Zomerdijk; Fakhredin A Sayed-Tabatabaei; Gianluca Trifirò; Stella C F Blackburn; Miriam C J M Sturkenboom; Sabine M J M Straus
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

3.  What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association.

Authors:  Andreas Vilhelmsson; Tommy Svensson; Anna Meeuwisse; Anders Carlsten
Journal:  BMC Clin Pharmacol       Date:  2011-10-25

4.  Number of patients studied prior to approval of new medicines: a database analysis.

Authors:  Ruben G Duijnhoven; Sabine M J M Straus; June M Raine; Anthonius de Boer; Arno W Hoes; Marie L De Bruin
Journal:  PLoS Med       Date:  2013-03-19       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.